Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921101 | 0.85 | HTT (0.39) | RAB9APOLBHTTMEN1KMT2A | |
| SCHEMBL2919368 | 0.79 | MAPT (0.42) | CYP1A2RAB9APOLBHTTMEN1 | |
| SCHEMBL7029119 | 0.78 | MEN1 (0.43) | CYP1A2RAB9APOLBHTTMEN1 | |
| SCHEMBL2916877 | 0.77 | CYP1A2 (0.44) | CYP1A2AMY1AMEN1KMT2A | |
| SCHEMBL28017843 | 0.72 | CYP1A2 (0.51) | CYP1A2POLBHTTMEN1KMT2A | |
| SCHEMBL29098567 | 0.70 | CYP1A2 (0.54) | CYP1A2AMY1ARAB9APOLBHTT | |
| SCHEMBL5746519 | 0.70 | CYP1A2 (0.49) | CYP1A2POLBHTTMEN1KMT2A | |
| SCHEMBL502270 | 0.69 | CYP1A2 (0.64) | CYP1A2POLBHTTMEN1KMT2A | |
| SCHEMBL9599309 | 0.69 | CYP1A2 (0.51) | CYP1A2POLBHTTMEN1KMT2A | |
| SCHEMBL508751 | 0.68 | HTT (0.55) | CYP1A2POLBHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | CYP1A2 2726/4885AMY1A 4308/4885RAB9A 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.